The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 301–400 of 4,628
Optimizing quality of life in patients with idiopathic pulmonary fibrosis
van Manen, M. J. G., Geelhoed, J. J. M., Tak, N. C., & Wijsenbeek, M. S. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816686743 · Cited by 124
Knipe, R. S., Probst, C. K., Lagares, D., Franklin, A., Spinney, J. J., Brazee, P. L., Grasberger, P. E., Zhang, L., Black, K. E., Sakai, N., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0075oc · Cited by 134
Fra-2–expressing macrophages promote lung fibrosis
Ucero, A. C., Bakiri, L., Roediger, B., Suzuki, M., Jiménez, M., Mandal, P., Braghetta, P., Bonaldo, P., Paz-Ares, L. G., Torre, C. F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125366 · Cited by 131
“The current treatment options for IPF, including lung transplantation and the recently approved nintedanib and pirfenidone (6, 7), are limited, and there is an urgent need for new therapeutic targets.”
BackgroundCollard, H. R., Chen, S., Yeh, W., Li, Q., Lee, Y.-C., Wang, A., & Raghu, G. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201412-553oc · Cited by 125
Self-citationFunctional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis
Jacob, J., Bartholmai, B. J., Rajagopalan, S., Kokosi, M. A., Maher, T. M., Nair, A., Karwoski, R. A., Renzoni, E. A., Walsh, S. L. F., Hansell, D. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00379-2017 · Cited by 122
Self-citationNew Insights into Hippo/YAP Signaling in Fibrotic Diseases
Mia, M. M., & Singh, M. K. (2022) · Cells · doi:10.3390/cells11132065 · Cited by 125
Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis
Kim, E. S., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0350-9 · Cited by 116
Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening
Moua, T., Westerly, B. D., Dulohery, M. M., Daniels, C. E., Ryu, J. H., & Lim, K. G. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.12.026 · Cited by 115
Neighbors, M., Cabanski, C. R., Ramalingam, T. R., Sheng, X. R., Tew, G. W., Gu, C., Jia, G., Peng, K., Ray, J., Ley, B., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30185-1 · Cited by 121
Self-citationAhangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K. M., Wang, X., Justet, A., Adams, T. S., Readhead, B. P., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202010-3832oc · Cited by 123
Joannes, A., Brayer, S., Besnard, V., Marchal-Sommé, J., Jaillet, M., Mordant, P., Mal, H., Borie, R., Crestani, B., & Mailleux, A. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00185.2015 · Cited by 122
Cough in idiopathic pulmonary fibrosis
van Manen, M. J. G., Birring, S. S., Vancheri, C., Cottin, V., Renzoni, E. A., Russell, A., & Wijsenbeek, M. S. (2016) · European Respiratory Review · doi:10.1183/16000617.0090-2015 · Cited by 119
Self-citationPrognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 127
Vainshelboim, B., de Oliveira, J. J. F., Fox, B. D., Soreck, Y., Fruchter, O., & Kramer, M. R. (2015) · Lung · doi:10.1007/s00408-015-9703-0 · Cited by 117
“Long-term effective treatment, apart from lung transplantation, is still limited for most IPF patients despite some encouraging recent findings with pharmacotherapy [1, 3–5].”
ResultIdiopathic non‐specific interstitial pneumonia
Belloli, E. A., Beckford, R., Hadley, R. J., & Flaherty, K. R. (2015) · Respirology · doi:10.1111/resp.12674 · Cited by 125
Self-citationNon-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes
Withana, N. P., Ma, X., McGuire, H. M., Verdoes, M., van der Linden, W. A., Ofori, L. O., Zhang, R., Li, H., Sanman, L. E., Wei, K., et al. (2016) · Scientific Reports · doi:10.1038/srep19755 · Cited by 119
Self-citationJoshee, S. R., Vatti, N., & Chang, C. C.-C. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.12.017 · Cited by 139
Targeting FGFR for cancer therapy
Zhang, P., Yue, L., Leng, Q., Chen, C., Gan, C., Ye, T., & Cao, D. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01558-1 · Cited by 133
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
Nintedanib: First Global Approval
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-014-0335-0 · Cited by 123
Ono, M., Ohkouchi, S., Kanehira, M., Tode, N., Kobayashi, M., Ebina, M., Nukiwa, T., Irokawa, T., Ogawa, H., Akaike, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.217 · Cited by 119
Russell, A., Ripamonti, E., & Vancheri, C. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0171-y · Cited by 111
Kalchiem‐Dekel, O., Galvin, J. R., BURKE, A. P., Atamas, S. P., & Todd, N. W. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120476 · Cited by 124
“Side effects with these two medications may be substantial and thus careful decision making with individual patients weighing benefits versus risks is appropriate [5,181,184].”
BackgroundAlysandratos, K., Russo, S. J., Petcherski, A., Taddeo, E. P., Acín‐Pérez, R., Villacorta-Martín, C., Jean, J., Mulugeta, S., Rodríguez, L. R., Blum, B. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109636 · Cited by 125
“…been a major hurdle in developing effective therapies, and the two currently FDA-approved drugs pirfenidone and nintedanib, both aimed at inhibiting fibrogenic fibroblasts, have been shown to slow but not reverse the progression of lung function decline (King et al., 2014; Richeldi et al., 2014).”
BackgroundNoskovičová, N., Petřek, M., Eickelberg, O., & Heinzelmann, K. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0294tr · Cited by 131
Radiation-Induced Lung Fibrosis: Preclinical Animal Models and Therapeutic Strategies
Jin, H. K., Yoo, Y., Kim, Y.-H., Kim, Y., Cho, J., & Lee, Y. (2020) · Cancers · doi:10.3390/cancers12061561 · Cited by 127
“However, regimens for IPF, such as pirfenidone and nintedanib, help to reduce clinical exacerbations that affect pulmonary function [3,4].”
BackgroundTreatment of fibrotic interstitial lung disease: current approaches and future directions
Johannson, K. A., Chaudhuri, N., Adegunsoye, A., & Wolters, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01826-2 · Cited by 135
Brindisi, M., Saraswati, A. P., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00924 · Cited by 125
Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis
Guler, S. A., Ellison, K., Algamdi, M., Collard, H. R., & Ryerson, C. J. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201801-067oc · Cited by 121
Self-citationPhase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Khalil, N., Manganas, H., Ryerson, C. J., Shapera, S., Cantin, A. M., Hernandez, P., Turcotte, É. E., Parker, J. M., Moran, J., Albert, G. R., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00663-2018 · Cited by 119
“Both drugs slowed the progression of lung function decline by approximately 50% as compared to placebo in large Phase 3 clinical studies [25, 26].”
BackgroundSelf-citationDemographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Kaunisto, J., Salomaa, E.-R. M., Hodgson, U., Kaarteenaho, R. L., Kankaanranta, H., Koli, K. M., Vahlberg, T. J., & Myllärniemi, M. (2019) · ERJ Open Research · doi:10.1183/23120541.00170-2018 · Cited by 121
Tanner, L., Single, A., Bhongir, R. K. V., Heusel, M., Mohanty, T., Karlsson, C. A. Q., Pan, L., Clausson, C.-M., Bergwik, J., Wang, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36314-5 · Cited by 123
Sheth, J. S., Belperio, J. A., Fishbein, M. C., Kazerooni, E. A., Lagstein, A., Murray, S., Myers, J. L., Simon, R. H., Sisson, T. H., Sundaram, B., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.09.028 · Cited by 116
Self-citationAutotaxin and chronic inflammatory diseases
Magkrioti, C., Galaris, A., Kanellopoulou, P., Stylianaki, E.-A., Kaffe, E., & Aidinis, V. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102327 · Cited by 116
Bowman, W. S., Newton, C. A., Linderholm, A., Neely, M. L., Pugashetti, J. V., Kaul, B., Vo, V., Echt, G., Leon, W., Shah, R., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00503-8 · Cited by 114
Pulmonary rehabilitation for interstitial lung disease
Dowman, L., Hill, C. J., May, A., & Holland, A. E. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006322.pub4 · Cited by 309
Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis
Foster, M. W., Morrison, L. D., Todd, J. L., Snyder, L. D., Thompson, J. W., Soderblom, E. J., Plonk, K., Weinhold, K. J., Townsend, R. C., Minnich, A., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr501149m · Cited by 115
Maher, T. M., Molina-Molina, M., Russell, A.-M., Bonella, F., Jouneau, S., Ripamonti, E., Axmann, J., & Vancheri, C. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0468-5 · Cited by 108
Kaushik, S. S., Freeman, M. S., Yoon, P., Liljeroth, M., Stiles, J. V., Roos, J. E., Foster, W. S. M., Rackley, C. R., McAdams, H. P., & Driehuys, B. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00326.2014 · Cited by 105
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
Martínez, F. J., Chisholm, A., Collard, H. R., Flaherty, K. R., Myers, J. L., Raghu, G., Walsh, S. L. F., White, E. S., & Richeldi, L. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30325-3 · Cited by 121
Self-citationTAZ contributes to pulmonary fibrosis by activating profibrotic functions of lung fibroblasts
Noguchi, S. F., Saito, A., Mikami, Y., Urushiyama, H., Horie, M., Matsuzaki, H., Takeshima, H., Makita, K., Miyashita, N., Mitani, A., et al. (2017) · Scientific Reports · doi:10.1038/srep42595 · Cited by 109
Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
Hunninghake, G. M., Quesada-Arias, L. D., Carmichael, N. E., Manzano, J. M. M., Poli, S., Baumgartner, M. A., DiGianni, L. M., Gampala-Sagar, S., Leone, D. A., Gulati, S., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1571oc · Cited by 119
Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients
Ali, R. M. M., & Ghonimy, M. B. I. (2021) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-021-00484-3 · Cited by 125
Althobiani, M. A., Russell, A., Jacob, J., Ranjan, Y., Folarin, A., Hurst, J. R., & Porter, J. C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1296890 · Cited by 147
Ley, B., Bradford, W. Z., Vittinghoff, E., Weycker, D. A., du Bois, R. M., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1546oc · Cited by 104
Self-citationMaher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Rohr, K. B., Michael, A., Ittrich, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30255-3 · Cited by 120
Self-citationFibroblast growth factor‐1 attenuates TGF ‐β1‐induced lung fibrosis
Shimbori, C., Bellaye, P., Jiaji, X., Gauldie, J., Ask, K., Ramos, C., Becerril, C., Pardo, A., Selman, M., & Kolb, M. R. J. (2016) · The Journal of Pathology · doi:10.1002/path.4768 · Cited by 115
Self-citationReactive oxygen species as signaling molecules in the development of lung fibrosis
González-González, F. J., Chandel, N. S., Jain, M., & Budinger, G. R. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.09.005 · Cited by 110
Mitochondrial Dysfunction in Pulmonary Fibrosis
Rangarajan, S., Bernard, K. F., & Thannickal, V. J. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-370aw · Cited by 115
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1103-4 · Cited by 113
Self-citationAnti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
Sato, S., Shinohara, S., Hayashi, S., Morizumi, S., Abe, S., Okazaki, H., Chen, Y., Goto, H., Aono, Y., Ogawa, H., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0654-2 · Cited by 108
Interstitial Pneumonia with Autoimmune Features
Graney, B. A., & Fischer, A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201808-565cme · Cited by 108
Richeldi, L., Kreuter, M., Selman, M., Crestani, B., Kirsten, A., Wuyts, W. A., Xu, Z., Bernois, K., Stowasser, S., Quaresma, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209701 · Cited by 110
Self-citationNi, K., Liu, M., Zheng, J. H., Wen, L., Chen, Q., Xiang, Z., Lam, K.-T., Liu, Y., Chan, G., Lau, Y., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0326oc · Cited by 110
Interstitial Lung Abnormality: Recognition and Perspectives
Hatabu, H., Hunninghake, G. M., & Lynch, D. A. (2018) · Radiology · doi:10.1148/radiol.2018181684 · Cited by 103
Cellular senescence and radiation-induced pulmonary fibrosis
He, Y., Thummuri, D., Zheng, G., Okunieff, P. G., Citrin, D. E., Vujašković, Ž., & Zhou, D. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.006 · Cited by 116
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
Fisher, M., Nathan, S. D., Hill, C., Marshall, J. D., Dejonckheere, F., Thuresson, P.-O., & Maher, T. M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s17 · Cited by 103
Machine learning in radiology: the new frontier in interstitial lung diseases
Barnes, H., Humphries, S. M., George, P., Assayag, D., Glaspole, I., Mackintosh, J. A., Corte, T. J., Glassberg, M. K., Johannson, K. A., Calandriello, L., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00230-8 · Cited by 119
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
Self-citationIdiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Alam, P., Abdelhameed, A. S., Rajpoot, R. K., & Khan, R. H. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.02.009 · Cited by 101
Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
Kyung, S. Y., Kim, D. Y., Yoon, J. Y., Son, E. S., Kim, Y. J., Park, J. W., & Jeong, S. H. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0204-7 · Cited by 101
Self-citationRaghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vašáková, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30172-9 · Cited by 103
Self-citationPanyain, N., Godinat, A., Lanyon‐Hogg, T., Lachiondo‐Ortega, S., Will, E. J., Soudy, C., Mondal, M., Mason, K., Elkhalifa, S., Smith, L. M., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04527 · Cited by 106
Udwadia, Z., Koul, P. A., & Richeldi, L. (2020) · Lung India · doi:10.4103/lungindia.lungindia_818_20 · Cited by 110
Self-citationFalcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 108
The state of the art for artificial intelligence in lung digital pathology
Viswanathan, V. S., Toro, P., Corredor, G., Mukhopadhyay, S., & Madabhushi, A. (2022) · The Journal of Pathology · doi:10.1002/path.5966 · Cited by 115
Raghu, G., Mouded, M., Chambers, D. C., Martínez, F. J., Richeldi, L., LANCASTER, L. H., Hamblin, M. J., Gibson, K. F., Rosas, I. O., Prasse, A., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2824oc · Cited by 109
Self-citationPirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Chianese, M. I., Screm, G., Salton, F., Confalonieri, P., Trotta, L., Barbieri, M., Ruggero, L., Mari, M., Reccardini, N., Geri, P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060709 · Cited by 128
“To date, the pharmacological options for the treatment of IPF are Nintedanib and Pirfenidone, two drugs designed to slow disease progression that have shown to have similar effects in real life [6,7,31–36].”
BackgroundDempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202007-901oc · Cited by 101
MUC5B and Idiopathic Pulmonary Fibrosis
Yang, I. V., Fingerlin, T. E., Evans, C. M., Schwarz, M. I., & Schwartz, D. A. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201503-110aw · Cited by 120
Patients with IPF and lung cancer: diagnosis and management
Τzouvelekis, Α., Spagnolo, P., Bonella, F., Vancheri, C., Tzilas, V., Crestani, B., Kreuter, M., & Bouros, D. E. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30478-2 · Cited by 100
Koo, H. Y., El-Baz, L. M. F., House, S., Cilvik, S. N., Dorry, S. J., Shoukry, N. M., Salem, M. L., Hafez, H. S., Dulin, N. O., Ornitz, D. M., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5106 · Cited by 100
“In the first place, the amounts of FGF2 used far exceed endogenous FGF2 described in vivo after lung injury and in IPF [18–20,22].”
BackgroundInfluentialGu, L., Larson‐Casey, J. L., Andrabi, S. A., Lee, J. H., Meza‐Perez, S., Randall, T. D., & Carter, A. B. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101307 · Cited by 106
Aronson, K. I., Danoff, S. K., Russell, A., Ryerson, C. J., Suzuki, A., Wijsenbeek, M. S., Bajwah, S., Bianchi, P., Corte, T. J., Lee, J. S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202105-1193st · Cited by 111
Self-citationTang, H., Gao, L., Mao, J., He, H., Liu, J., Cai, X., Lin, H., & Wu, T. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-015-0654-4 · Cited by 105
“Encouragingly, pirfenidone (an antifibrotic and antiinflammatory agent) and nintedanib (a tyrosine kinase inhibitor) have recently been demonstrated to reduce the decline in forced vital capacity (King et al. 2014; Richeldi et al. 2014).”
BackgroundTashiro, J., Elliot, S. J., Gerth, D. J., Xia, X., Pereira‐Simon, S., Choi, R., Catanuto, P., Shahzeidi, S., Toonkel, R. L., Shah, R. H., et al. (2015) · Translational research · doi:10.1016/j.trsl.2015.09.004 · Cited by 109
Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study
Raimundo, K., Chang, E. Y., Broder, M. S., Alexander, K., Zazzali, J. L., & Swigris, J. J. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0165-1 · Cited by 107
Walsh, S. L. F., Maher, T. M., Kolb, M. R. J., Poletti, V. E., Nusser, R., Richeldi, L., Vancheri, C., WILSHER, M. L., Antoniou, K. M., Behr, J., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00936-2017 · Cited by 100
Self-citationSAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)
Raghu, G., Richeldi, L., Crestani, B., Wung, P. K., Bejuit, R., Espéret, C., Antoni, C., & Soubrane, C. (2018) · European Respiratory Journal · doi:10.1183/13993003.01130-2018 · Cited by 105
Self-citationBermejo-Peláez, D., Ash, S. Y., Washko, G. R., Estépar, R. S. J., & Ledesma‐Carbayo, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-56989-5 · Cited by 109
Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
Balestro, E., Calabrese, F., Turato, G., Lunardi, F., Bazzan, E., Marulli, G., Biondini, D., Rossi, E., Sanduzzi, A., Rea, F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154516 · Cited by 105
Kurita, Y., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Tsubouchi, K., Sato, N., Yoshida, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0600-3 · Cited by 106
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
May, J. M., Mitchell, J. A., & Jenkins, G. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172058 · Cited by 114
FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis
Staab-Weijnitz, C. A., Fernandez, I. E., Knüppel, L., Maul, J., Heinzelmann, K., Juan-Guardela, B. M., Hennen, E., Preißler, G., Winter, H., Neurohr, C., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2233oc · Cited by 100
van den Blink, B., Dillingh, M. R., Ginns, L. C., Morrison, L. D., Moerland, M., Wijsenbeek, M. S., Trehu, E., Bartholmai, B. J., & Burggraaf, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.00850-2015 · Cited by 102
End-of-life care of patients with idiopathic pulmonary fibrosis
Rajala, K., Lehto, J. T., Saarinen, M., Sutinen, E., Saarto, T., & Myllärniemi, M. (2016) · BMC Palliative Care · doi:10.1186/s12904-016-0158-8 · Cited by 102
Optimising experimental research in respiratory diseases: an ERS statement
Bonniaud, P., Fabre, A., Frossard, N., Guignabert, C., Inman, M. D., Kuebler, W. M., Maes, T., Shi, W., Stämpfli, M. R., Uhlig, S., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02133-2017 · Cited by 103
Self-citationMitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts
Schuliga, M. J., Pechkovsky, D. V., Read, J. M., Waters, D. W., Blokland, K. E. C., Reid, A. T., Hogaboam, C. M., Khalil, N., Burgess, J. K., Prêle, C. M., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13855 · Cited by 106
“danib have been shown to reduce the rate of decline in lung function and increase progression free survival in IPF, albeit with significant side effects.(3,4) These positive developments have encouraged renewed interest in identification of alternative and complementary drug targets.”
BackgroundMaher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 103
Self-citationKato, M., Sasaki, S., Nakamura, T., Kurokawa, K., Yamada, T., Ochi, Y., Ihara, H., Takahashi, F., & Takahashi, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-48593-4 · Cited by 106
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Richeldi, L., Kolb, M. R. J., Jouneau, S., Wuyts, W. A., Schinzel, B., Stowasser, S., Quaresma, M., & Raghu, G. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-1030-4 · Cited by 105
Self-citationTherapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease
Worthington, E. N., & Hagood, J. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072318 · Cited by 100
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 149
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Goldberg, H. J., Collard, H. R., El‐Chemaly, S., Flaherty, K. R., Hunninghake, G. M., Lasky, J. A., Lederer, D. J., Machado, R. F., Martínez, F. J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.052 · Cited by 101
Self-citationTargeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis
Espíndola, M. S., Habiel, D. M., Narayanan, R., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1519oc · Cited by 96
Self-citationWuyts, W. A., Wijsenbeek, M. S., Bondue, B., Bouros, D. E., Bresser, P., Cordeiro, C. R., Hilberg, O., Magnusson, J. M., Manali, E. D., Morais, A., et al. (2019) · Respiration · doi:10.1159/000504763 · Cited by 101
Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis
Zhang, F., Ayaub, E. A., Wang, B., Puchulu‐Campanella, E., Li, Y., Hettiarachchi, S. U., Lindeman, S. D., Luo, Q., Rout, S., Srinivasarao, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012034 · Cited by 103
“While nintedanib is known to inhibit platelet-derived growth factor receptor, fibroblast growth factor receptor, and vascular endothelial growth factor receptor (Richeldi et al, 2014), how inhibition of these tyrosine kinases mediates suppression of fibrosis has not been established.”
BackgroundFibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis
Selvarajah, B., Azuelos, I., Anastasiou, D., & Chambers, R. C. (2021) · Science Signaling · doi:10.1126/scisignal.aay1027 · Cited by 104
Ovarian cancer standard of care: are there real alternatives?
Pepa, C. D., Tonini, G., Pisano, C., Napoli, M. D., Cecere, S. C., Tambaro, R., Facchini, G., & Pignata, S. (2015) · 癌症:英文版 · doi:10.5732/cjc.014.10274 · Cited by 108
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.